Abstract Number: PB0847
Meeting: ISTH 2022 Congress
Theme: Platelets and Megakaryocytes » Platelet Function and Interactions
Background: Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by persistent thrombocytopenia due to autoantibody binding to platelet antigens causing their premature destruction by the reticuloendothelial system.
Aims: Following study was conducted to determine the likelihood of positive ANA markers in adult ITP patients and other autoimmune conditions along with their management.
Methods: This prospective observational study was conducted from January to December 2021 after taking informed consent. Patient’s medical history, clinical data and outcome was collected using patients performa and analyzed using SPSS version 23.
Results: A total of 143 patients were screened for ANA. This includes 38 males (26.6%), 105 females (73.4%) with a median age of 38 years (IQR-25), 94 acute ITP (64.7%) and 49 chronic ITP (34.3%). ANA markers were positive in 41(28.7%), AMA and ASMA in 28(19.6%) patients. The frequency of positive ANA was higher in females 32(78%) as compared to males 8(22%) and in acute 25(61.0%) as compared to chronic 16(39%) ITP patients. Among 41(27.3%) positive ANA patients, 6(15.38%) had systemic lupus erythematosus (SLE) and 1(2.4%) patient had hypothyroidism. Lab parameters showed significant difference with median platelet (24 IQR-49 vs 81 IQR-178 vs 82.5 IQR-150) x109/L and hemoglobin (12.05 g/dl IQR-3 vs 12.06 IQR-2 vs 12.40 IQR 2) from baseline to 3 months and follow-up with (p value= ≤0.001).Frequency of bleeding symptoms is presented in Figure 1. Skin related complications observed includes alopecia in 3(2.09%) and skin rashes in 4(2.79%), whereas 11(7.6%) patients had history of abortions. Overall treatment response is presented in Table 1.
Conclusion(s): Overall treatment response with first and second line therapy in acute (90.4%) and chronic (94.9%) ITP patients was observed to be effective with decreased bleeding symptoms. However prevalence of 28.7% of ANA indicates concerns for developing other autoimmune conditions such as SLE.
To cite this abstract in AMA style:
Borhany M, Zafar S, Abid M, Shamsi T. Management of adult idiopathic thrombocytopenic purpura (ITP) patients with antinuclear antibody (ANA) [abstract]. https://abstracts.isth.org/abstract/management-of-adult-idiopathic-thrombocytopenic-purpura-itp-patients-with-antinuclear-antibody-ana/. Accessed March 21, 2024.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/management-of-adult-idiopathic-thrombocytopenic-purpura-itp-patients-with-antinuclear-antibody-ana/